Tegafur

Tegafur (FT 207; NSC 148958) is a chemotherapeutic 5-FU proagent used in the treatment of cancers; is a component of tegafur-uracil.

Product Specifications

CAS Number

[17902-23-7]

Product Name Alternative

FT 207; NSC 148958

UNSPSC

12352005

Hazard Statement

H301, H311, H331

Target

Nucleoside Antimetabolite/Analog

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Tegafur.html

Purity

99.95

Solubility

DMSO : ≥ 48 mg/mL|H2O : ≥ 20 mg/mL

Smiles

O=C1NC(C(F)=CN1C2OCCC2)=O

Molecular Formula

C8H9FN2O3

Molecular Weight

200.17

Precautions

H301, H311, H331

References & Citations

[1]Sotaro Sadahiro, Toshiyuki Suzuki, Akira Tanaka, et al. Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response to oral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer. Cancer Chemotherapy and Pharmacology. 2012, 70 (2) : 285-291.|[2]José L. Ariasa, et al. Engineering of an antitumor (core/shell) magnetic nanoformulation based on the chemotherapy agent ftorafur. Colloids and Surfaces A: Physicochemical and Engineering Aspects. 2011,384 (1-3) : 157-163.|[3]Gabriel N. Hortobagyi, William Heim, Laura Hutchins, et al. A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer. Cancer. 2010, 116 (6) : 1440-1445.|[4]K. Fujita, H. Nakayama, W. Ichikawa, et al. Pharmacokinetics of 5-Fluorouracil in Elderly Japanese Patients with Cancer Treated with S-1 (a Combination of Tegafur and Dihydropyrimidine Dehydrogenase Inhibitor 5-Chloro-2,4-dihydroxypyridine) . Drug Metab Dispos. 2009 Jul;37 (7) :1375-7. doi: 10.1124/dmd.109.027052. Epub 2009 Apr 23.|[5]Tegafur-uracil